RT Journal Article SR Electronic T1 A novel mechanism of HIF2-dependent PLK1-mediated metastasis and drug resistance of clear cell Renal Cell Carcinoma JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.02.05.20020552 DO 10.1101/2020.02.05.20020552 A1 Maeva Dufies A1 Annelies Verbiest A1 Lindsay S Cooley A1 Papa Diogop Ndiaye A1 Julien Viotti A1 Xingkang He A1 Nicolas Nottet A1 Wilfried Souleyreau A1 Anais Hagege A1 Stephanie Torrino A1 Julien Parola A1 Sandy Giuliano A1 Delphine Borchiellini A1 Renaud Schiappa A1 Baharia Mograbi A1 Jessica Zucman-Rossi A1 Karim Bensalah A1 Alain Ravaud A1 Patrick Auberger A1 Andréas Bikfalvi A1 Emmanuel Chamorey A1 Nathalie Rioux-Leclercq A1 Nathalie M. Mazure A1 Benoit Beuselinck A1 Yihai Cao A1 Jean Christophe Bernhard A1 Damien Ambrosetti A1 Gilles Pagès YR 2020 UL http://medrxiv.org/content/early/2020/02/07/2020.02.05.20020552.abstract AB Polo-Like Kinase 1 (Plk1) expression is inversely correlated with survival advantages in many cancers. However, molecular mechanisms that underlie Plk1 expression are poorly understood. Here, we uncover a novel hypoxia-regulated mechanism of Plk1-mediated cancer metastasis and drug resistance. We demonstrated that a new HIF-2-dependent regulatory pathway drives Plk1 expression in clear cell renal cell carcinoma (ccRCC). Mechanistically, HIF-2 transcriptionally targets the hypoxia response element of the Plk1 promoter. In ccRCC patients, high expression of Plk1 was correlated to poor disease-free survival and overall survival. Loss-of-function of Plk1 in vivo markedly attenuated ccRCC growth and metastasis. High Plk1 expression conferred a resistant phenotype of ccRCC to targeted therapeutics such as sunitinib, in vitro, in vivo and in metastatic ccRCC patients. Importantly, high Plk1 expression was defined in a subpopulation of ccRCC patients that are refractory to current therapies. Hence, we propose a therapeutic paradigm for improving outcomes of ccRCC patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the French Association for Cancer Research (ARC), the Fondation de France, the Ligue Nationale contre le Cancer (Equipe Labellisée 2019) the French National Institute for Cancer Research (INCA) and the FX Mora Foundation. This study was conducted as part of the Centre Scientifique de Monaco Research Program, funded by the Government of the Principality of Monaco. The samples from Bordeaux and associated data were collected, selected and made available within the framework of the project clinicobiological National Cancer Database Kidney UroCCR supported by l’Institut National du Cancer (INCa).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data are included in the manuscript, details can be requested by email to the corresponding autor